FIA
KLDO

FNY Investment Advisers’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

FNY Investment Advisers’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,000
Closed -$14K – 1194
2019
Q1 		$14K Buy
+1,000
New +$13.8K ﹤0.01% 434

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

FNY Investment Advisers's KLDO Position: Q2 2019 in Review

FNY Investment Advisers sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2019, closing a stake of 1,000 shares — an estimated $14K sold.

FNY Investment Advisers first reported a position in KLDO in Q1 2019 and held it in 1 quarter. The position peaked at $14K in Q1 2019. 37 funds tracked by Wall St. Rank hold KLDO as of Q2 2019.

  • FNY Investment Advisers reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 1,000 Kaleido Biosciences, Inc. Common Stock shares in Q2 2019, an estimated $14K.
  • FNY Investment Advisers first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • FNY Investment Advisers's Kaleido Biosciences, Inc. Common Stock position peaked at $14K in Q1 2019.
  • 37 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2019.

Based on FNY Investment Advisers's 13F filing for Q2 2019, filed 24 Jul 2019.